January 31, 2023
1 minute read
CDC researchers have found that vaccination with a bivalent messenger RNA booster is effective against the XBB.1.5 subvariant of SARS-CoV-2.
The relative efficacy of bivalent boosters against XBB- or XBB.1.5-associated symptomatic infections was 49%, 40%, and was 43%. Last week’s infectious disease top article.
Another top story is Anthony S. Fauci, MD On why he was drawn to the field of infectious diseases.
Read these and other top stories about infectious diseases below.
CDC Releases First Estimates of Bivalent Booster Efficacy for XBB.1.5
For the first time, the CDC estimated how effective a bivalent COVID-19 vaccine would be against the latest predominant Omicron subvariant of SARS-CoV-2. read more.
Anthony S. Fauci, MD obsessed with identity
What drew me to infectious diseases was the enormous impact they can have not only on individuals, but on society as well. read more.
The FDA Committee Lezafungin candidaemia and invasiveness Candidiasis
The FDA Antimicrobial Advisory Committee voted 14 to 1 in favor of rezafungin for the treatment of candidaemia and invasive candidiasis. read more.
Actual impact of nirmatrelvir and ritonavir on SARS-CoV-2 infection
As the COVID-19 pandemic enters its fourth year, it’s a good time to reflect on the progress made for people with mild to moderate illness who do not require hospitalization. read more.
FDA Commission Approves Plan To Simplify COVID-19 vaccination
An FDA advisory panel has voted unanimously in favor of a plan to streamline and simplify COVID-19 vaccine formulation in the United States. By replacing the first primary dose with a bivalent vaccine currently used as a booster. read more.